---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-24-000060"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2024-07-24T23:59:59+00:00"
generated_at: "2026-05-31T17:42:52.965922+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q2 net sales $4.12B (+14.5% reported), adj EPS $0.62, above guidance; acquires Silk Road Medical

## Summary
- Q2 net sales $4.120B, up 14.5% reported (16.1% operational, 14.7% organic); GAAP EPS $0.22, adjusted EPS $0.62 vs guidance $0.57-$0.59.
- Cardiovascular segment sales grew 17.8% reported; MedSurg grew 9.0%; U.S. sales up 16.9%.
- Received China NMPA approval for FARAPULSE PFA System; launched AGENT Drug-Coated Balloon in U.S. and received China NMPA approval.
- Announced agreement to acquire Silk Road Medical (SILK) for stroke prevention; subject to customary closing conditions.
- FY2024 guidance: reported sales growth 13.5-14.5%, adj EPS $2.38-$2.42; Q3 guidance: adj EPS $0.57-$0.59.

## SEC filing metadata
- accession: 0000885725-24-000060
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2024-07-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572524000060/0000885725-24-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572524000060/bsx-20240724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-24-000060
- JSON: https://secwatch.observer/filing/0000885725-24-000060.json
- Plain text: https://secwatch.observer/filing/0000885725-24-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.